Document is current
Any future updates will be listed below
-
Authors
Yu, Peimin
Wu, Xintong
Cui, Li
Pan, Songqing
Han, Yanbing
Xu, Huiqin
Zhu, Suiqiang
Wang, Xuefeng
Huang, Huapin
Wang, Tiancheng
Liao, Weiping
Zhang, Ming
Tang, Liou
Sun, Hongbin
Qin, Bing
Hu, Zhiping
Feng, Juan
Chen, Yangmei
Zhang, Meiyun
Li, Qifu
Han, Xiong
Xiao, Bo
Chen, Huisheng
Li, Luoqing
Liang, Yanran
Ye, Hui
Liu, Yutong
Hong, Zhen
Zhou, Dong https://orcid.org/0000-0001-7101-4125
-
Funding
Funding for this research was provided by:
SK Biopharmaceuticals Co., Ltd
Ignis Therapeutics (Shanghai) Limited
- License Information
-
More Information
Article History
Received: 12 September 2025
Accepted: 5 November 2025
First Online: 22 December 2025
Declarations
:
: Peimin Yu, Xintong Wu, Li Cui, Songqing Pan, Yanbing Han, Huiqin Xu, Suiqiang Zhu, Xuefeng Wang, Huapin Huang, Tiancheng Wang, Weiping Liao, Ming Zhang, Liou Tang, Hongbin Sun, Bing Qin, Zhiping Hu, Juan Feng, Yangmei Chen, Meiyun Zhang, Qifu Li, Xiong Han, Bo Xiao, Huisheng Chen, Luoqing Li, Yanran Liang, Zhen Hong, and Dong Zhou have no conflicts of interest to declare. All authors have read and approved the manuscript. Yutong Liu and Hui Ye are employees of Ignis Therapeutics (Shanghai) Limited, China.
: This trial on which the post hoc analyses are based was conducted in accordance with the International Conference on Harmonisation notes for Guidance on Good Clinical Practice, in addition to any applicable country-specific regulations and the Declaration of Helsinki. The original trial protocols were approved by independent ethics committees or institutional review boards according to local regulations at each site. Informed consent was obtained from all individual participants included in the study before enrolment.
